Documents
Application Sponsors
BLA 761119 | Lundbeck Seattle BioPharmaceuticals, Inc. | |
Marketing Status
Application Products
001 | INJECTABLE;INJECTION | 100MG/ML | 0 | VYEPTI | EPTINEZUMAB-JJMR |
FDA Submissions
TYPE 1; Type 1 - New Molecular Entity | ORIG | 1 | AP | 2020-02-21 | STANDARD |
LABELING; Labeling | SUPPL | 2 | AP | 2021-09-24 | STANDARD |
LABELING; Labeling | SUPPL | 6 | AP | 2022-10-21 | STANDARD |
Submissions Property Types
ORIG | 1 | Null | 6 |
SUPPL | 2 | Null | 7 |
SUPPL | 6 | Null | 15 |
CDER Filings
Lundbeck Seattle BioPharmaceuticals, Inc.
cder:Array
(
[0] => Array
(
[ApplNo] => 761119
[companyName] => Lundbeck Seattle BioPharmaceuticals, Inc.
[docInserts] => ["",""]
[products] => [{"drugName":"VYEPTI","activeIngredients":"EPTINEZUMAB-JJMR","strength":"100MG\/ML","dosageForm":"INJECTABLE;INJECTION","marketingStatus":"Prescription","te":"None","rld":"No","rs":"No"}]
[labels] => [{"actionDate":"02\/21\/2020","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/761119s000lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"02\/21\/2020","submission":"ORIG-1","actionType":"Approval","submissionClassification":"","reviewPriority":"N\/A","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/761119s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2020\\\/761119Orig1s000ltr.pdf\"},{\"name\":\"Review\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2020\\\/761119Orig1s000TOC.cfm\"}]","notes":">"}]
[supplements] =>
[actionDate] => 2020-02-21
)
)